We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year Allschwil, Switzerland, October 10, 2024 Basilea...
Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus Allschwil, 10. Oktober 2024 Basilea Pharmaceutica...
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX:...
Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis Allschwil, 24. September 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN...
Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung Bereitstellung eines...
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding Initial funding of USD 29 million to support development of Basilea’s clinical...
Starke Cresemba® (Isavuconazol)-Verkäufe in Europa lösen USD 25 Mio. Umsatzmeilensteinzahlung an Basilea aus Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 6. September 2024 Basilea...
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September...
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea Ad hoc...
Entscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Cresemba® (Isavuconazol) bei Kindern und Verlängerung der Marktexklusivität löst CHF 10 Mio. Meilensteinzahlung an Basilea...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 46.2 | 46.2 | 46.2 | 1000 | 46.2 | DE |
4 | 0 | 0 | 46.2 | 46.2 | 46.2 | 1020 | 46.2 | DE |
12 | 0 | 0 | 46.2 | 46.2 | 46.2 | 892 | 46.2 | DE |
26 | 0 | 0 | 46.2 | 46.2 | 46.2 | 981 | 46.2 | DE |
52 | 0 | 0 | 46.2 | 46.2 | 46.2 | 2620 | 46.2 | DE |
156 | 0 | 0 | 46.2 | 46.2 | 46.2 | 4099 | 46.2 | DE |
260 | 0 | 0 | 46.2 | 46.2 | 46.2 | 3847 | 46.2 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions